WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
Africa Energy Indaba highlights prospects of South Africa
Mainland urges Taiwan to publish truth of fatal boat incident
Senate passes reauthorization of key US surveillance program
Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
How major US stock indexes fared Friday, 4/19/2024
Chinese scientist awarded for groundbreaking work in transplantation, cellular therapy
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
William Contreras drives in 2 runs for Brewers in a 2
Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
Ryan Reynolds says Michael J. Fox helped his late father James 'feel less alone' in his 20